PROTEOME SCIENCES PLC

Management Reports • Apr 25, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2782D

Proteome Sciences PLC

25 April 2017

Proteome Sciences plc

("Proteome Sciences" or the "Company")

AGM Statement and Result of AGM

At the Company's AGM held today the Chairman, Christopher Pearce, made the following statement:

"As stated in our recent results, we expect 2017 to be a transformational year for Proteome Sciences.  The combination of strong revenue growth during 2016 and operational initiatives to simplify our strategy, consolidate our resources and broaden our commercial capability, have put the Company in a good position to take advantage of the increasing opportunities afforded by quantitative proteomics. Trading remains in line with management expectations."  

All resolutions at the AGM were duly passed.

For further information: Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer                          Tel: +44 (0)1932 865065
Dr Ian Pike, Chief Scientific Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson	Tel: +44 (0)20 7220 0500
Tony Quirke (broking) IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan	Tel: +44 (0)20 3053 8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMPGUGWCUPMGPA